Creative Medical Technology (NASDAQ:CELZ) Shares Cross Below Fifty Day Moving Average – Should You Sell?

Shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.98 and traded as low as $1.75. Creative Medical Technology shares last traded at $1.86, with a volume of 37,374 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Creative Medical Technology in a report on Monday, December 29th. Wall Street Zen cut shares of Creative Medical Technology from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce”.

Creative Medical Technology Stock Performance

The stock has a fifty day simple moving average of $1.97 and a two-hundred day simple moving average of $2.71. The stock has a market cap of $4.85 million, a PE ratio of -0.65 and a beta of 2.09.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC acquired a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is owned by institutional investors and hedge funds.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.